Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of ND0612 in Parkinson's Disease
NCT02096601Phase 1Completed
- Sponsor
- NeuroDerm Ltd.
- Start
- Aug 2014
- Primary completion
- Mar 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of levodopa and carbidopa in Parkinson's disease (PD) (2 arms), sponsored by NeuroDerm Ltd. Primary endpoints: Adverse events frequency up to 6 weeks, LD, CD and 3-OMD PK analysis and 1 more. Started Aug 2014; status: completed.
02
Drugs
levodopacarbidopa
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT02096601.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02096601.